‘Top-down’ treatment strategy dramatically improves outcomes for Crohn’s patients
Approximately 80% of patients taking Remicade from diagnosis had symptoms controlled
Read More
Tag: Remicade
Subcutaneous Remsima launched in UK
The new option is the first and only subcutaneous formulation of the drug.
Read More
CMA drops anti-competitive case against MSD
The CMA has closed its investigation into a suspected anti-competitive discount scheme by MSD, findings no grounds for action.
Read More
NICE approves Xeljanz for Ulcerative Colitis
The National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Xeljanz for adults with moderate to severe active ulcerative colitis.
Read More
EU nod for Sandoz’ Remicade biosimilar Zessly
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck & Co’s Remicade
Read More
Pfizer, Celltrion say data backs switch to Remicade biosimilar
Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
Read More
EU review for Sandoz’ Humira, Remicade biosimilars
European regulators have accepted for review Sandoz’ marketing applications for biosimilars to AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab).
Read More
MSD accused of breaching UK competition law
The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by MSD for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market.
Read More
US green light for Remicade biosimilar
US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications.
Read More
Biosimilar Inflectra matches Remicade efficacy in trial
Pfizer and Celltrion have unveiled Phase III study data comparable safety and efficacy between biosmilar Inflectra and reference drug Remicade in patients with moderate-to-severe Crohn’s disease (CD).
Read More
UK launch for Biogen’s biosimilar infliximab
Biogen has launched Flixabi – a biosimilar of Johnson & Johnson’s blockbuster infliximab – across the UK for use in a range of chronic inflammatory conditions.
Read More
EU nod for Samsung Bioepis’ Remicade biosimilar
Samsung Bioepis’ biosimilar of Johnson & Johnson’s blockbuster anti-inflammatory infliximab has won regulatory approval in Europe, potentially further expanding access to anti-TNF therapies in the region.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
